Stockscreener 앱 받기
133.26
2.25%
-3.07
시간 외 거래:
133.26
Insmed Inc 주식(INSM)의 최신 뉴스
Vanguard’s Larger Passive Stake Puts Insmed’s Volatile Story In Focus - Yahoo Finance
Earnings Preview: Insmed to Report Financial Results Pre-market on May 07 - Moomoo
Jennison Associates LLC Decreases Position in Insmed, Inc. $INSM - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Purchases New Position in Insmed, Inc. $INSM - MarketBeat
Insmed executives line up two healthcare investor conference talks in May - Stock Titan
Vanguard (NASDAQ: INSM) reports 11.5M Insmed shares, 5.34% stake - Stock Titan
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Insmed (INSM) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Insmed to Present at May 2026 Investor Conferences - PR Newswire
Book value per share of Insmed Incorporated – LSE:0JAV - TradingView
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Insmed drops skin disorder candidate after mid-stage trial setback - MSN
Vanguard Group Inc. Has $3.67 Billion Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: United Therapeutics (UTHR), Insmed (INSM) and MannKind (MNKD) - The Globe and Mail
Pictet Asset Management Holding SA Sells 181,864 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Stock Hits Day Low of $134.72 Amid Price Pressure - Markets Mojo
Non-Cystic Fibrosis Bronchiectasis Pipeline Set for Significant Expansion by 2026 with 12+ Therapies and Robust Clinical Progress from Haisco Pharmaceutical, CSL Behring, Insmed, Zambon | DelveInsight - Barchart
Insmed ends Brinsupri development in skin disease post study failure - MSN
Insmed, Inc. $INSM Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Insmed (INSM) Slips 6% as Investors Continue to Digest Failed HS Trial and Reposition Ahead of Upcoming Earnings - Moomoo
Insmed (INSM) slips 6% as investors continue to digest failed HS trial and reposition ahead of upcoming earnings - Quiver Quantitative
Insmed (NASDAQ:INSM) Trading Down 5.9%What's Next? - MarketBeat
The ESG Growth Portfolio's Insmed Inc(INSM) Holding History - GuruFocus
Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models - Yahoo Finance
How The Insmed (INSM) Investment Story Is Shifting On Brinsupri And ENCORE Developments - Yahoo Finance
KLP Kapitalforvaltning AS Has $12.88 Million Stock Position in Insmed, Inc. $INSM - MarketBeat
INSM|Insmed Inc|Price:135.170|Chg%:-8.66 - TradingKey
The 'worst-case scenario' — why Insmed just reversed after a 181% six-month sprint - MSN
Insmed’s TPIP Extension Study Completion: What Long-Term PH-ILD Data Could Mean for INSM Investors - TipRanks
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 - Financial Times
INSMED EV-to-OCF: -30.50 | Fairly Valued - GuruFocus
Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Insmed, Inc. $INSM - MarketBeat
M&T Bank Corp Grows Stock Position in Insmed, Inc. $INSM - MarketBeat
Asset Management One Co. Ltd. Purchases Shares of 80,887 Insmed, Inc. $INSM - MarketBeat
Insmed Inc stock (US4576693075): Is the rare disease pipeline strong enough to unlock new upside? - AD HOC NEWS
Insmed Incorporated (INSM) Stock Analysis: Potential 47% Upside With Strong Buy Ratings - DirectorsTalk Interviews
Mirae Asset Global Investments Co. Ltd. Acquires 69,410 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Stock Hits Day Low of $135.73 Amid Price Pressure - Markets Mojo
GF Fund Management CO. LTD. Grows Stake in Insmed, Inc. $INSM - MarketBeat
KBC Group NV Buys 24,396 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Reiterates by Roth Capital -- Price Target Maintained at $2 - GuruFocus
Insmed chair and CEO William Lewis sells $1.54m in stock - Investing.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
INSMED (INSM) CEO exercises options and sells 10,699 shares under 10b5-1 plan - Stock Titan
Roth Mkm Reaffirms "Buy" Rating for Insmed (NASDAQ:INSM) - MarketBeat
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - Moomoo
William Lewis lists INSM share sales (NASDAQ: INSM) in Form 144 filing - Stock Titan
Guggenheim raises Insmed stock price target to $230 on Arikayce By Investing.com - Investing.com Canada
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Insmed, Inc. (NASDAQ:INSM) Short Interest Update - MarketBeat
Insmed Inc stock (US4576693075): Is brensocatib approval the real test for rare disease growth? - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Purchases Shares of 435,442 Insmed, Inc. $INSM - MarketBeat
INSM Maintained by RBC Capital -- Price Target Raised to $216 - GuruFocus
Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says - Moomoo
Oak Ridge Investments LLC Trims Position in Insmed, Inc. $INSM - MarketBeat
3.22%
자본화:
|
볼륨(24시간):